New drugs for the treatment of type 2 diabetes.
Insights into the pathogenesis of type 2 diabetes has led to increasing therapeutic targets for intervention, and improvements in peptide delivery technology have lead to non-injection methods of insulin delivery. This article reviews new drugs which are likely to become available for use by people with diabetes over the coming year.
Chowdhury
Tahseen A
TA
Department of Diabetes and Metabolism, The Royal London Hospital, London.
Hossain
Belayet
B
D058892:Adenosine Deaminase Inhibitors; D000280:Administration, Inhalation; D000682:Amyloid; D063387:Cannabinoid Receptor Antagonists; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D018819:Dipeptidyl Peptidase 4; D054873:Dipeptidyl-Peptidase IV Inhibitors; D005544:Forecasting; D052216:Glucagon-Like Peptide 1 / Q000037:antagonists & inhibitors; D006023:Glycoproteins / Q000037:antagonists & inhibitors; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000008:administration & dosage; D058228:Islet Amyloid Polypeptide; D013678:Technology, Pharmaceutical / Q000639:trends*
D058892:Adenosine Deaminase Inhibitors; D000682:Amyloid; D063387:Cannabinoid Receptor Antagonists; D054873:Dipeptidyl-Peptidase IV Inhibitors; D006023:Glycoproteins; D007004:Hypoglycemic Agents; D007328:Insulin; D058228:Islet Amyloid Polypeptide; D052216:Glucagon-Like Peptide 1; C042807:DPP4 protein, human; D018819:Dipeptidyl Peptidase 4